Physician profile

Dillon Gibson

Cleveland, OH

NPI 1548764129

$573.58

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$75.53

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $201.85 2022
Pfizer INC. $128.18 2021-2023
Boehringer Ingelheim Pharmaceuticals, INC. $53.11 2022
Lantheus Medical Imaging, INC. $46.12 2022-2023 Definity
E.R. Squibb & Sons, L.L.C. $43.22 2022-2023
Esperion Therapeutics, INC. $37.86 2022
Astrazeneca Pharmaceuticals LP $25.08 2022
Boston Scientific Corporation $23.43 2024 Watchman Flx
Genzyme Corporation $14.73 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Dillon Gibson

$573.58

in general payments reported 2019-2025

Years
2021-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/11418846/dillon-gibson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.